Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

• Sponsor: Stanford University (Other)
• Overall Status: Withdrawn
• CT.gov ID: NCT00226993
• Collaborator: National Institutes of Health (NIH) (NIH)
• Enrollment: 0

Study Details

Study Description

Brief Summary

This is a single institution phase I / II trial to evaluate the safety and efficacy of intratumoral CpG injections combined with local radiation in patients with mycosis fungoides. Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 (2 Gy each day). CpG injections will be administered into the same tumor site within 24 hours before or 24 hours after each radiation treatment. Weekly doses of (intratumoral or peritumoral injections) CpG will be then administered subcutaneously in the region of previous injections for 23 additional doses. The total treatment duration is 24 weeks.

Condition or Disease	Intervention/Treatment	Phase
Mycosis Fungoides	Drug: CPG 7909	Phase 1/Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 0 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study of Intratumoral Injection of CPG 7909, A TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides
• Study Start Date: Mar 1, 2005
• Anticipated Primary Completion Date: Dec 1, 2006

Outcome Measures

Primary Outcome Measures

1. Safety and efficacy of intratumoral CpG injections combined with local radiation []

Secondary Outcome Measures

1. To determine local and systemic anti-tumor effect. []

2. To evaluate tumor-specific humoral and cellular immune responses []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:- Biopsy confirmed mycosis fungoides of stage IB-IVA. Patients must have failed or have been intolerant of at least 2 topical or one systemic treatment.

• Patients must have at least one site of disease that is accessible for intratumoral injection of CpG percutaneously, and the second site to follow treatment response.

• 18 years of age or older

• Karnofsky Performance Status (KPS) of > 70.

• Adequate bone marrow function: WBC>4,000uL, hemoglobin > 10g/dL; platelet count

100,000/mm^3; ANC> 1000.

• Adequate hepatic function: bilirubin <= 1.5 mg/dL; SGOT/SGPT<3xupper limit of normal

• Adequate renal function: serum creatinine <= 2.0mg/dL.

• Required wash out periods for prior therapy:

• Topical therapy: 2 weeks

• Chemotherapy: 4 weeks

• Radiotherapy (including photo therapy): 4 weeks

• Systemic biological therapy for mycosis fungoides: 4 weeks

• Other investigational therapy: 4weeks

• Patients of reproductive potential and their partners must agree to use an effective (>90% reliability) form of contraception during the study and for 4 weeks following the last study drug administration.

• Women of reproductive potential must have negative urine pregnancy test.

• Life expectancy greater than 4 months.

• Able to comply with the treatment schedule. Exclusion Criteria:- Pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.

• Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active, prior treatment, or both).

• Patients with active infection or with a fever >38.50 C within three days prior to the first scheduled treatment.

• CNS metastases

• Prior malignancy (active within 5 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.

• Prior treatment with CpG.

• History of allergic reactions attributed to compounds of similar composition to CPG 7909

• Current anticoagulant therapy (ASA<= 325mg/day allowed).

• Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).

• Pregnant or lactating.

• Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Stanford University
• National Institutes of Health (NIH)

Investigators

• Principal Investigator: Ronald Levy, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ronald Levy, Robert K. and Helen K. Summy Professor in the School of Medicine, Stanford University
• ClinicalTrials.gov Identifier: NCT00226993
• Other Study ID Numbers: LYMNHL0021; 95850; LYMNHL0021
• First Posted: Sep 27, 2005
• Last Update Posted: Dec 1, 2016
• Last Verified: Nov 1, 2016

• Additional relevant MeSH terms: Mycoses; Mycosis Fungoides

Study Results

No Results Posted as of Dec 1, 2016